<ul data-eligibleForWebStory="false"><li>Ahmedabad-based biopharma startup Lamark Biotech raised ₹6.5 crore in a pre-Series A funding round led by IAN Group and other investors.</li><li>Lamark Biotech focuses on drug delivery innovations for chronic diseases using its proprietary ProteoStrong platform to stabilize protein-based therapeutics like insulin.</li><li>The startup plans to use the funding to advance its thermostable insulin formulation, InsulinStrong, crucial for regions with poor cold chain infrastructure.</li><li>Lamark Biotech aims to expand its biologics pipeline, file international patents, conduct early clinical trials, and establish partnerships with pharmaceutical companies and global health organizations.</li></ul>

Lamark Biotech Raises ₹6.5 Cr in Pre-Series A Round to Advance Thermostable Insulin Innovation

Discover more